FC
RNAM

Finepoint Capital’s Avidity Biosciences RNAM Stock Holding History

Finepoint Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-380,700
Closed -$11.2M – 20
2025
Q1 		$11.2M Sell
380,700
-10,600
-3% -$330K 0.86% 12
2024
Q4 		$11.4M Buy
+391,300
New +$16.4M 0.69% 16

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Finepoint Capital's RNAM Position: Q2 2025 in Review

Finepoint Capital sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 380,700 shares — an estimated $11.2M sold.

Finepoint Capital first reported a position in RNAM in Q4 2024 and held it in 2 quarters. The position peaked at $11.4M in Q4 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • Finepoint Capital reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • Finepoint Capital sold 380,700 Avidity Biosciences shares in Q2 2025, an estimated $11.2M.
  • Finepoint Capital first reported a position in Avidity Biosciences in Q4 2024 and held it in 2 quarters.
  • Finepoint Capital's Avidity Biosciences position peaked at $11.4M in Q4 2024.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.